General Information
- All abstracts can only be submitted via the Online Abstract Submission System.
- Abstract submission deadline: August 1st 2023. Any editing (or removal) of the abstract is possible before the deadline.
- Any abstracts sent by email will not be processed or accepted. Pending submission will also not be considered for the review process. Also ensure for not making multiple submissions.
- Upon submission, a confirmation email will be sent.
- In need of abstract submission assistance please contact ainm23@mic.umcg.nl
- Notification about abstract acceptance: July 15th 2023. Please also check spam or junk folder in the email. Accepted abstracts will be invited for either Poster sessions or Selected Oral sessions, and will be published in Frontiers in Nuclear Medicine.
- Upon acceptance, the authors will register as participants (with early- bird price).
- Any withdrawal for the submitted abstract needs to be made by email notification at the latest 10 September 2023. Withdrawals after the specified date are still accepted, but abstracts may still appear in publications.
- All authors of the accepted abstracts will be asked to agree to the following statements. Without agreement the submission cannot be finalized:
- I understand that the abstract will be published as submitted and will not be proofread.
- I understand that the copyright of the submitted abstract goes - in case of publication - to Frontiers in Nuclear Medicine.
- I confirm to have read the data protection regulations and accept the electronic data processing of all information I entered during the process of this abstract submission, especially regarding the information of all named co-authors in this scientific work.
Abstracts Submission
- All abstract must be submitted (and will be presented) in English.
- Abstracts must contain original material neither published nor presented elsewhere before.
- Abstracts of which only parts of the data had been submitted at other congresses, are allowed for submission.
- Abstracts concerning a still ongoing study can be submitted. In case of acceptance, it is of course possible to implement the latest findings in the final presentation.
- Submissions of different studies by the same author/author group are allowed.
- Abstracts must not contain the following items:
- Trademarks. Use generic drug names. The use of commercial drug names, brands, and registered trademarks is strictly prohibited.
- Drugs should be referred to by the active substance or pharmacological designation.
- Trademarks of Medical Devices: Use generic names/descriptions. No commercial names or brands of medical devices should be mentioned.
- Company names and location
- Websites and email addresses
- Title: Be specific, short, and describe best the content and scope of the abstract. Do not include authors, institutions, city names, trademarks, company names and locations, websites, email addresses and abbreviations in the title.
- Topic: Select the best matching topic based on the abovementioned topic. The abstract review and selection process will be performed based on the selected topic.
- Body: Abstracts must not exceed 350 words (excluding title and authors) and should be well structured stating:
- Aim/Introduction:
- Materials and Methods:
- Results:
- Conclusion:
- References:
- Abstracts may not include graphics or pictures. Simple tables can be included for the review process but will be removed in all publications